Summary of Product Characteristics
last updated on the eMC:
16/07/2007
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 16/07/2007 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.8 - Undesirable Effects
|
| Date of revision of text on the SPC: 01/2007 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Section 4.8 (undesirable effects) section updated to included the following;
Patients treated with dopamine agonists for the treatment of Parkinson's disease including quinagolide, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of the dose or treatment discontinuation.
|
|
Updated on 15/06/2005 and displayed until 16/07/2007
|
Reasons for adding or updating:
|
|
|
|
